harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this ...

Median time to response was 5.3 months (range: 1.6, 11.2). Among patients with BRAF fusion or rearrangement (n=64), the ORR was 52%. In patients with BRAF V600E mutation (n=12), the ORR was 50%.

When examining hiPSC-derived neural cells with the NF1 deletion or KIAA1549: BRAF fusion, the team observed increased cell growth and ERK activation, which decreased when treated with an MEK ...

The nod sanctions the type 2 RAF inhibitor to be used in tumors with a BRAF fusion or rearrangement, or BRAF V600 mutation. The go-ahead puts Ojemda toe to toe with Novartis’ Tafinlar-Mekinist ...

OJEMDA™ (tovorafenib) is the first FDA-approved treatment for relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or V600 mutation, following the pivotal Phase II trial ...

The common effect through all these breakpoint variants is the formation of an oncogenic BRAF–KIAA1549 fusion incorporating the BRAF kinase domain, but lacking the amino-localized autoinhibitory ...

OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 ...

OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 ...

The deal comes three months after Ojemda secured accelerated FDA approval as a treatment for pLGG in patients 6 months and older whose tumors have a BRAF fusion or rearrangement, or a BRAF V600 ...